ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >protein tyrosine kinase >Poziotinib (HM781-36B)

Poziotinib (HM781-36B)

Poziotinib (HM781-36B) Suppliers list
Company Name: Jurong Coupling Biotechnology Co., Ltd.
Tel: 13656108824
Email: coupling278191416@hotmail.com
Products Intro: Product Name:Poziotinib (HM781-36B)
CAS:1092364-38-9
Purity:99% HPLC Package:5KG;1KG
Company Name: ATK CHEMICAL COMPANY LIMITED
Tel: +86 21 5161 9050/ 5187 7795
Email: ivan@atkchemical.com
Products Intro: CAS:1092364-38-9
Purity:98% HPLC Package:5MG;10MG;50MG;100MG,1G,5G
Company Name: career henan chemical co
Tel: +86-371-86658258
Email: sales@coreychem.com
Products Intro: Product Name: Poziotinib (HM781-36B)
CAS: 1092364-38-9
Purity:99% Package:1KG;7USD
Company Name: TianYuan Pharmaceutical CO.,LTD
Tel: +86-755-23284190 13684996853
Email: sales@tianpharm.com
Products Intro: Product Name:Poziotinib
CAS:1092364-38-9
Purity:99% Package:10g 100g 200g 500g 1kg 5kg per barrel
Company Name: Accela ChemBio Inc.
Tel: (+1)-858-699-3322
Email: info@accelachem.com
Products Intro: Product Name:1-[4-[[4-[(3,4-Dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-2-propen-1-one
CAS:1092364-38-9
Purity:98% Package:0.25g;1g Remarks:SY235762

Lastest Price from Poziotinib (HM781-36B) manufacturers

  • Poziotinib
  • US $15.00-10.00 / KG
  • 2021-07-13
  • CAS:1092364-38-9
  • Min. Order: 1KG
  • Purity: 99%+ HPLC
  • Supply Ability: Monthly supply of 1 ton
  • Poziotinib
  • US $15.00-10.00 / KG
  • 2021-07-10
  • CAS:1092364-38-9
  • Min. Order: 1KG
  • Purity: 99%+ HPLC
  • Supply Ability: Monthly supply of 1 ton
  • Poziotinib
  • US $15.00-10.00 / KG
  • 2021-07-02
  • CAS:1092364-38-9
  • Min. Order: 1KG
  • Purity: 99%+ HPLC
  • Supply Ability: Monthly supply of 1 ton

Related articles

Poziotinib (HM781-36B) Basic information
Description In vitro Description In vivo Application
Product Name:Poziotinib (HM781-36B)
Synonyms:1-[4-[[4-[(3,4-Dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-2-propen-1-one;Poziotinib;UNII-OEI6OOU6IK;1-(4-((4-((3,4-dichloro-2-fluorophenyl)aMino)-7- Methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one;1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one;poziotinib(HM-78136B);NOV120101;1-[4-[[4-[(3,4-Dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-2-propen-1-one Poziotinib
CAS:1092364-38-9
MF:C23H21Cl2FN4O3
MW:491.34
EINECS:
Product Categories:Inhibitors;API
Mol File:1092364-38-9.mol
Poziotinib (HM781-36B) Structure
Poziotinib (HM781-36B) Chemical Properties
Boiling point 629.7±55.0 °C(Predicted)
density 1.409±0.06 g/cm3(Predicted)
pka5.35±0.30(Predicted)
CAS DataBase Reference1092364-38-9
Safety Information
MSDS Information
Poziotinib (HM781-36B) Usage And Synthesis
DescriptionPoziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.
In vitroPoziotinib specifically inhibits the cell growth in HER2 amplified gastric cancer cells, and inhibits the phosphorylation of EGFR and key components of downstream signaling cascades such as STAT3, AKT and ERK. Poziotinib also induces apoptosis and G1 cell cycle arrest by activating the mitochondrial pathway in HER2 amplified gastric cancer cells. Furthermore, Poziotinib also exerts synergistic effects with chemotherapeutic agents in both HER2 amplified and HER2 non-amplified gastric cancer cells.
Description

Poziotinib [1. {4. [4. (3,4. Dichloro.2.monofluoroaniline) -7-methoxyquinazoline-6. Oxygen]. 1. Piperidinyl} propan-2-ene-1one (1)] is a novel oral cancer cell inhibitor developed by Seoul Medical University in South Korea in 2008. It is used for the treatment of breast and gastric cancer, and has targeted Small molecule inhibitor of tyrosine kinase. It is currently in Phase II / III clinical research and can be used alone or in combination for the treatment of gastric, non-small cell lung cancer and breast cancer. Poziotinib is resistant to erlotinib and gefitinib EGFR L858R / T790M Double mutant cells have a strong inhibitory effect.
The combined use of Poziotinib (HM781-36B) and 5-fluorouracil, platinum compound, paclitaxel or gemcitabine shows a good synergistic inhibitory effect on the overexpression of human epidermis No. 2 (HER2). A new third-generation anti-tumor cell inhibitor following the kinase inhibitor afatinib.

In vivoIn nude mice bearing N87 human gastric cancer xenografts, Poziotinib (0.5 mg/kg p.o.) alone significantly inhibits the growth of tumors, and coadministraion of Poziotinib and 5-FU causes more effective tumor inhibition. In addition, HM781-36B shows excellent antitumor activity in a variety of EGFR-and HER-2-dependent tumor xenograft models, including erlotinib-sensitive HCC827 NSCLC cells, erlotinib-resistant NCI-H1975 NSCLC cells, HER-2 overexpressing Calu-3 NSCLC cells, NCI-N87 gastric cancer cells, SK-Ov3 ovarian cancer cells and EGFR-overexpressing A431 epidermoid carcinoma cancer cells.
Application

Poziotinib is suitable for the treatment of patients with advanced NSCLC with exon 20 mutations in EGFR. Multiple patients have proven effective. Poziotinib is also valuable for patients with advanced NSCLC who are resistant to first-generation EGFR TKI and T790M / MET negative. There are no clinical data on the treatment of patients with brain metastases by Poziotinib. One patient with advanced NSCLC with exon 20 mutation in EGFR had meningeal metastases. This patient has been taking Poziotinib for effective control for 4 months.

DescriptionPoziotinib is a TKI that covalently and irreversibly inhibits EGFR and HER2, and is unique because of its small terminal group and flexible quinazoline core. Its small size and flexibility allow it to evade the steric hindrance which affects other EGFR TKIs [138].
Tag:Poziotinib (HM781-36B)(1092364-38-9) Related Product Information
Genistein Dacomitinib (PF299804) Irbinitinib XL-647 AZD 3759 AG 1478 HYDROCHLORIDE OSI-420 Anlotinib EGF816 Neratinib CO-1686 AZD-9291 PD168393 Nilotinib PD 0325901 IPI 145 AZD8931 Canertinib